Gilead ( GILD) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day down 1.7%. By the end of trading, Gilead fell $1.12 (-2.2%) to $50.27 on light volume. Throughout the day, 5.6 million shares of Gilead exchanged hands as compared to its average daily volume of 9.2 million shares. The stock ranged in price between $50.19-$51.09 after having opened the day at $50.86 as compared to the previous trading day's close of $51.39. Other company's within the Health Care sector that declined today were: Synergy Pharmaceuticals ( SGYP), down 20.9%, Alexza Pharmaceuticals ( ALXA), down 19.7%, Anika Therapeutics ( ANIK), down 17%, and Cadence Pharmaceuticals ( CADX), down 16.7%. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $39.31 billion and is part of the drugs industry. The company has a P/E ratio of 14.5, below the average drugs industry P/E ratio of 15.5 and below the S&P 500 P/E ratio of 17.7. Shares are up 25.6% year to date as of the close of trading on Thursday. Currently there are 20 analysts that rate Gilead a buy, no analysts rate it a sell, and five rate it a hold. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.